Down-regulation of hematopoiesis master regulator PU.1 via aberrant methylation in chronic myeloid leukemia
First Online: 07 June 2012 Received: 11 September 2011 Revised: 07 May 2012 Accepted: 11 May 2012 DOI:
Cite this article as: Yang, H., Liang, H., Yan, J. et al. Int J Hematol (2012) 96: 65. doi:10.1007/s12185-012-1106-x Abstract
The PU.1 transcription factor is a crucial regulator of hematopoiesis, and its expression is altered in various leukemic processes. It has been shown that expression of PU.1 is severely impaired in patients with chronic myeloid leukemia (CML), but the mechanism underlying this effect remains unknown. Through bisulfite sequencing, semi-quantitative PCR, and indirect immunofluorescence and Western blot techniques, we found aberrant methylation in the promoter region of transcription factor PU.1 in CML patients both in the chronic and blast crisis phases, as well as in the CML blast K562 cell line. Of these, several CpG sites were more highly methylated in blast crisis than chronic phase, while no methylation of these sites was observed in healthy individuals. Interestingly, CML patients achieved complete cytogenetic remission under imatinib mesylate treatment, but the aberrant methylation status of PU.1 was not reversed. Down-regulation of PU.1 expression at the mRNA and protein levels was also observed in association with aberrant methylation. Thus, for the first time, we have revealed a potential epigenetic modification of PU.1 in CML, which may be responsible for the down-regulation of PU.1. These data suggest that aberrant methylation of PU.1 may play a role in CML pathogenesis, and may therefore serve as a useful biomarker and potential target for demethylating drugs.
Keywords Chronic myeloid leukemia Transcription factor PU.1 DNA methylation
H. Yang and H. Liang contributed equally to this work.
Quintás-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc. 2006;81(7):973–88.
Ito T, Nishiyama C, Nakano N, et al. Roles of PU.1 in monocyte- and mast cell-specific gene regulation: PU.1 transactivates CIITA pIV in cooperation with IFN-gamma. Int Immunol. 2009;21(7):803–16.
Oikawa T, Yamada T, Kihara-Negishi F, et al. The role of Ets family transcription factor PU.1 in hematopoietic cell differentiation, proliferation and apoptosis. Cell Death Differ. 1999;6(7):599–608.
Kosmider O, Denis N, Lacout C, et al. Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice. Cancer Cell. 2005;8(6):467–78.
Dakic A, Wu L, Nutt SL. Is PU.1 a dosage-sensitive regulator of haemopoietic lineage commitment and leukaemogenesis? Trends Immunol. 2007;28(3):108–14.
Rosenbauer F, Wagner K, Kutok JL, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet. 2004;36(6):624–30.
Zhang S-J, Ma L-Y, Huang Q-H, et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc Natl Acad Sci USA. 2008;105(6):2076–81.
Albajar M, Gutierrez P, Richard C, et al. PU.1 expression is restored upon treatment of chronic myeloid leukemia patients. Cancer Lett. 2008;270(2):328–36.
Plass C, Soloway PD. DNA methylation, imprinting and cancer. Eur J Hum Genet. 2002;10(1):6–16.
Kinoshita T. Epigenetic inactivation of tumor suppressor genes in hematologic malignancies. Int J Hematol. 2004;80(2):108–19.
Yang MY, Chang JG, Lin PM, et al. Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3. Cancer Sci. 2006;97(12):1298–307.
Nguyen TT, Mohrbacher AF, Tsai YC, et al. Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications. Blood. 2000;95(9):2990–2.
Yang MY, Liu TC, Chang JG, et al. JunB gene expression is inactivated by methylation in chronic myeloid leukemia. Blood. 2003;101(8):3205–11.
Liu TC, Lin SF, Chang JG, et al. Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br J Haematol. 2003;123(4):654–61.
Tatetsu H, Ueno S, Hata H, et al. Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. Cancer Res. 2007;67(11):5328–36.
Dakic A, Metcalf D, Di Rago L, et al. PU.1 regulates the commitment of adult hematopoietic progenitors and restricts granulopoiesis. J Exp Med. 2005;201(9):1487–502.
Chou ST, Khandros E, Bailey LC, et al. Graded repression of PU.1/Sfpi1 gene transcription by GATA factors regulates hematopoietic cell fate. Blood. 2009;114(5):983–94.
DeKoter RP, Schweitzer BL, Kamath MB, et al. Regulation of the interleukin-7 receptor alpha promoter by the Ets transcription factors PU.1 and GA-binding protein in developing B cells. J Biol Chem. 2007;282(19):14194–204.
Kastner P, Chan S. PU.1: a crucial and versatile player in hematopoiesis and leukemia. Int J Biochem Cell Biol. 2008;40(1):22–7.
Cook WD, McCaw BJ, Herring C, et al. PU.1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutation of its DNA binding domain. Blood. 2004;104(12):3437–44.
Mueller BU, Pabst T, Osato M, et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood. 2002;100(3):998–1007.
Metcalf D, Dakic A, Mifsud S, et al. Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia. Proc Natl Acad Sci USA. 2006;103(5):1486–91.
Vangala RK, Heiss-Neumann MS, Rangatia JS, et al. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood. 2003;101(1):270–7.
Wang KK, Shi JT, Wang P, Zhu XH, He MM, Fang H, Du YZ, Zhang J. PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer Cell. 2010;17(2):186–97.
PubMed CrossRef Copyright information
© The Japanese Society of Hematology 2012